IDO2 and breast cancer: In addition, mRNA expressions of IDO1, IDO2 and HLA-G5 in breast cancer patients with pathological stage III were respectively 2.9, 607 and 113.7 fold more than ASCs compared to stage II, however this differences were not statistically significant ( P=0.32, 0.14 and 0.17, respectively, (Fig.2).